Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 304

1.

Safety and tolerability of TRAIL receptor agonists in cancer treatment.

Fulda S.

Eur J Clin Pharmacol. 2015 Feb 24. [Epub ahead of print]

PMID:
25704217
[PubMed - as supplied by publisher]
2.

Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo.

Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M.

Oncogenesis. 2015 Feb 9;4:e137. doi: 10.1038/oncsis.2014.51.

PMID:
25664930
[PubMed]
3.

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.

Michaelis M, Agha B, Rothweiler F, Löschmann N, Voges Y, Mittelbronn M, Starzetz T, Harter PN, Abhari BA, Fulda S, Westermann F, Riecken K, Spek S, Langer K, Wiese M, Dirks WG, Zehner R, Cinatl J, Wass MN, Cinatl J Jr.

Sci Rep. 2015 Feb 3;5:8202. doi: 10.1038/srep08202.

PMID:
25644037
[PubMed - in process]
Free PMC Article
4.

Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.

Hugle M, Fulda S.

Cancer Lett. 2015 Jan 28. pii: S0304-3835(14)00759-9. doi: 10.1016/j.canlet.2014.12.016. [Epub ahead of print]

PMID:
25637161
[PubMed - as supplied by publisher]
5.

Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy.

Fulda S, Kögel D.

Oncogene. 2015 Jan 26. doi: 10.1038/onc.2014.458. [Epub ahead of print] Review.

PMID:
25619832
[PubMed - as supplied by publisher]
6.

Targeting extrinsic apoptosis in cancer: Challenges and opportunities.

Fulda S.

Semin Cell Dev Biol. 2015 Jan 21. pii: S1084-9521(15)00008-7. doi: 10.1016/j.semcdb.2015.01.006. [Epub ahead of print] Review.

PMID:
25617598
[PubMed - as supplied by publisher]
7.

An Evidence-based Analysis of the Association between Periodic Leg Movements during Sleep and Arousals in Restless Legs Syndrome.

Ferri R, Rundo F, Zucconi M, Manconi M, Bruni O, Ferini-Strambi L, Fulda S.

Sleep. 2015 Jan 12. pii: sp-00630-14. [Epub ahead of print]

PMID:
25581922
[PubMed - as supplied by publisher]
8.

Smac mimetics as IAP antagonists.

Fulda S.

Semin Cell Dev Biol. 2014 Dec 27. pii: S1084-9521(14)00327-9. doi: 10.1016/j.semcdb.2014.12.005. [Epub ahead of print] Review.

PMID:
25550219
[PubMed - as supplied by publisher]
9.

Identification of IRF1 as critical dual regulator of Smac mimetic-induced apoptosis and inflammatory cytokine response.

Eckhardt I, Weigert A, Fulda S.

Cell Death Dis. 2014 Dec 11;5:e1562. doi: 10.1038/cddis.2014.498.

PMID:
25501823
[PubMed - in process]
10.

Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death.

Schoeneberger H, Belz K, Schenk B, Fulda S.

Oncogene. 2014 Nov 10. doi: 10.1038/onc.2014.338. [Epub ahead of print]

PMID:
25381820
[PubMed - as supplied by publisher]
11.

An evidence-based recommendation for a new definition of respiratory-related leg movements.

Manconi M, Zavalko I, Fanfulla F, Winkelman JW, Fulda S.

Sleep. 2015 Feb 1;38(2):295-304. doi: 10.5665/sleep.4418.

PMID:
25325500
[PubMed - in process]
12.

A small molecule inhibits protein disulfide isomerase and triggers the chemosensitization of cancer cells.

Eirich J, Braig S, Schyschka L, Servatius P, Hoffmann J, Hecht S, Fulda S, Zahler S, Antes I, Kazmaier U, Sieber SA, Vollmar AM.

Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12960-5. doi: 10.1002/anie.201406577. Epub 2014 Sep 26.

PMID:
25256790
[PubMed - in process]
13.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19.

PMID:
25236395
[PubMed - in process]
Free PMC Article
14.

Variants of the CNTNAP2 5' promoter as risk factors for autism spectrum disorders: a genetic and functional approach.

Chiocchetti AG, Kopp M, Waltes R, Haslinger D, Duketis E, Jarczok TA, Poustka F, Voran A, Graab U, Meyer J, Klauck SM, Fulda S, Freitag CM.

Mol Psychiatry. 2014 Sep 16. doi: 10.1038/mp.2014.103. [Epub ahead of print]

PMID:
25224256
[PubMed - as supplied by publisher]
15.

Synergistic interaction of Smac mimetic and IFNα to trigger apoptosis in acute myeloid leukemia cells.

Bake V, Roesler S, Eckhardt I, Belz K, Fulda S.

Cancer Lett. 2014 Dec 28;355(2):224-31. doi: 10.1016/j.canlet.2014.08.040. Epub 2014 Aug 29.

PMID:
25179908
[PubMed - in process]
16.

RIST: a potent new combination therapy for glioblastoma.

Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S, Debatin KM.

Int J Cancer. 2015 Feb 15;136(4):E173-87. doi: 10.1002/ijc.29138. Epub 2014 Sep 1.

PMID:
25123598
[PubMed - indexed for MEDLINE]
17.

Targeting inhibitor of apoptosis proteins for cancer therapy: a double-edge sword?

Fulda S.

J Clin Oncol. 2014 Oct 1;32(28):3190-1. doi: 10.1200/JCO.2014.56.8741. Epub 2014 Aug 11. No abstract available.

PMID:
25113757
[PubMed - indexed for MEDLINE]
18.

SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy.

Rettinger E, Glatthaar A, Abhari BA, Oelsner S, Pfirrmann V, Huenecke S, Kuçi S, Kreyenberg H, Willasch AM, Klingebiel T, Fulda S, Bader P.

Front Pediatr. 2014 Jul 18;2:75. doi: 10.3389/fped.2014.00075. eCollection 2014.

PMID:
25101252
[PubMed]
Free PMC Article
19.

The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer.

Braig S, Bischoff F, Abhari BA, Meijer L, Fulda S, Skaltsounis L, Vollmar AM.

Biochem Pharmacol. 2014 Sep 15;91(2):157-67. doi: 10.1016/j.bcp.2014.07.009. Epub 2014 Jul 25.

PMID:
25069048
[PubMed - indexed for MEDLINE]
20.

Therapeutic exploitation of necroptosis for cancer therapy.

Fulda S.

Semin Cell Dev Biol. 2014 Nov;35:51-6. doi: 10.1016/j.semcdb.2014.07.002. Epub 2014 Jul 25.

PMID:
25065969
[PubMed - in process]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk